Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

In any public health issue the people most impacted are Black people, Indigenous people and anyone who is at an intersection ...

Demonstrators gathered Thursday on the steps of the Department of Health and Human Services (HHS) building for a “die-in” ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...